“This Defies All Fiduciary Logic”: Curaleaf Fires Back at Aurora; Rival Deal Rumors Swirl

Curaleaf has escalated its confrontation with Aurora Cannabis, accusing the Canadian cannabis producer of denying it customary due diligence access while apparently entertaining interest from Organigram and British American Tobacco (BAT).

In a statement distributed to IgniteIt on Friday, October 9, Curaleaf challenged Aurora’s treatment of potential bidders and urged shareholders to demand that the company be included in any transaction process.

“We continue to be baffled by Aurora’s actions,” Curaleaf said.

The statement follows speculative reports that Organigram and BAT may be exploring a potential transaction involving Aurora.

The statement follows reporting by Cultivated’s Jeremy Berke that Organigram has explored a potential transaction with Aurora in recent weeks.

No competing offer was confirmed in the statement, but Curaleaf’s response suggests that the possibility of another bidder has intensified an already contentious takeover battle.

“We are outraged, and Aurora shareholders should be too,” the company said.

A $5 Offer Raises the Stakes

Curaleaf’s criticism comes just days after the company increased its acquisition proposal from $4 to $5 per Aurora share, a 25% increase intended to strengthen its case directly with shareholders.

Under the revised offer announced October 5, Aurora shareholders would receive $1 in cash and 0.4013 Curaleaf subordinate voting shares for each Aurora share tendered.

The $5 implied consideration represents an 86% premium to Aurora’s unaffected 30-day volume-weighted average share price of $2.75 as of August 10, according to Curaleaf. Because most of the consideration consists of shares, its market value will fluctuate with Curaleaf’s stock price.

The revised proposal also raises the maximum consideration to $6 per Aurora share, subject to the offer’s adjustment provisions.

Curaleaf formally filed the revised terms on October 6 and extended the offer’s expiration to December 4, 2026.

The company’s latest statement suggests that the increased consideration has done little to improve relations with Aurora’s board.

Curaleaf characterized the situation as one in which a company with an approximately $2.6 billion market capitalization is being excluded while a Canadian competitor valued at roughly $200 million appears to have access to the process.

“This defies all fiduciary logic and reason,” Curaleaf said.

Those market capitalization figures are Curaleaf’s characterizations, and the company has not provided evidence in its October 9 statement establishing that Organigram has received due diligence access.

Organigram and BAT Add a New Dimension

The potential involvement of Organigram Global and British American Tobacco introduces a different strategic possibility for Aurora.

Organigram is an established Canadian cannabis producer with an existing relationship with BAT, which has invested in the company and collaborated with it on cannabis research and development.

A transaction involving the two companies could offer Aurora an alternative to Curaleaf’s proposed combination, although the structure, financing and potential consideration of any such arrangement remain unconfirmed.

Curaleaf’s response focuses on the apparent difference in how potential counterparties are being treated.

“Curaleaf has addressed every request made of it, voluntarily agreed to provide disclosure that no regulator required, and increased its offer by 25%,” the company said.

The statement does not establish that Organigram or BAT has submitted a formal bid, or that Aurora has entered exclusive negotiations with either company.

For Aurora shareholders evaluating the available alternatives, Curaleaf has presented a publicly documented offer with defined consideration, while the reported Organigram–BAT interest has not yet produced publicly confirmed competing terms.

Aurora Has Resisted Curaleaf’s Approach

Aurora has repeatedly challenged Curaleaf’s hostile takeover attempt.

On October 5, following the announcement of Curaleaf’s enhanced proposal, Aurora reiterated its recommendation that shareholders take no action while its special committee evaluates the revised offer.

Aurora also pointed to its proceedings before the Alberta Securities Commission, saying its regulatory challenge had secured additional financial disclosure and a compliant bid timeline.

The company’s shareholder information website states that its board and special committee are evaluating strategic alternatives to maximize shareholder value, while acknowledging that a superior proposal may never emerge.

Curaleaf, meanwhile, argues that Aurora’s shareholders should have the opportunity to assess its proposal through a fair process.

In its October 9 statement, Curaleaf questioned whether investors would prefer exposure to a smaller Canadian cannabis business or ownership in a combined company with significant operations in both the United States and international medical markets.

Global Scale, Shareholder Value and the Cost of a Deal

Curaleaf has estimated that a combination with Aurora would create a cannabis business operating across 17 countries, generating more than $1.5 billion in trailing annual revenue and nearly $350 million in adjusted EBITDA.

The company also projects at least $40 million in annual cost synergies, largely from eliminating overlapping expenses and integrating operations. These figures are company estimates rather than independently established transaction outcomes.

For Curaleaf, Aurora’s international medical cannabis business offers an opportunity to expand its global footprint, particularly in markets where regulated medical cannabis distribution is developing.

For Aurora shareholders, the proposed consideration presents a different calculation. Accepting Curaleaf shares would provide participation in a larger, more geographically diversified cannabis business, but would also expose investors to Curaleaf’s balance sheet, operating performance and stock-price volatility.

Any competing proposal would need to be assessed against those economics, including its financing, execution risks and the amount of cash shareholders could receive.

The emergence of another interested party, even at the speculative stage, adds pressure to a process that has already become increasingly public.

Curaleaf’s latest statement ends by challenging Aurora shareholders to demand its inclusion in the process. With a revised offer now formally filed and the December 4 deadline approaching, the disagreement between the two companies has moved beyond valuation into the conduct of the sale process itself.

What’s Next for Cannabis M&A?

The Curaleaf–Aurora dispute illustrates how difficult cannabis consolidation can become when companies disagree over valuation, strategic fit and the terms of a transaction. Those issues are particularly consequential as operators seek access to capital and evaluate opportunities across increasingly interconnected international markets.

Cannabis executives, investors and financial advisers will have an opportunity to discuss the broader implications for capital allocation, valuations and federal policy at IgniteIt’s Capital & Policy Summit, taking place November 18 at the Grand Hyatt Washington in Washington, D.C. The event will bring industry decision-makers together to examine the policy and financing conditions shaping the next phase of cannabis investment.